Skip to content
Question
What will a month cost?
Read
7 min
Published
September 2026

Oral Tirzepatide: No Approved Pill, and What Compounded Versions Cost

Zepbound and Mounjaro are injections, so oral tirzepatide is a compounded product. What sellers charge for tablets and drops against the injection, why peptides absorb poorly by mouth, and what the research shows.

ByJenna PrattConsumer-access reporterPublished

Oral tirzepatide is not an approved drug. Every tirzepatide label on DailyMed is an injection. Zepbound comes as a single-dose pen, a single-dose vial, or a multi-dose vial and KwikPen, all given under the skin once a week[1]. Mounjaro comes in the same injectable presentations[2]. A tablet, capsule or drop sold as tirzepatide is made by a compounding pharmacy, and no FDA reviewer has checked that it works when swallowed.

That does not stop sellers from pricing it, and a reader comparing a compounded oral tirzepatide month against the weekly injection needs both numbers side by side. The oral market, the sublingual market and the injection market are below, each computed from the sellers that publish a monthly price.

What compounded oral tirzepatide costs

$265

Typical compounded oral month (37 sellers)

$249

Typical compounded sublingual month (9 sellers)

$249

Typical compounded injection month (361 sellers)

Oral prices run from $119 to $399 a month across 37 sellers, and those are the prices the sellers print before any membership, consult or shipping fee. Seller prices were read through September 2026.

The injection figure is the one on the tirzepatide price board, and the reasons that range is so wide are set out in compounded tirzepatide cost. What sits behind the low end of the injection market is in cheapest tirzepatide. A monthly price is only part of the bill, so run any quote through the all-in monthly calculator before comparing it with an injection quote that carries a different set of fees.

Why a peptide is hard to swallow

Peptides are broken down by stomach enzymes and cross the gut wall poorly. The one approved tablet version of a GLP-1 peptide, oral semaglutide, shows how much work it takes to get around that. Its tablets are made with an absorption enhancer called salcaprozate sodium (SNAC), and the label estimates absolute bioavailability at about 1% to 2% after a tablet, against 89% after a semaglutide injection[3].

The research that explained how the semaglutide tablet works found that absorption happens in the stomach, close to the surface of the tablet, and requires the drug to be coformulated with SNAC[4]. That work was done in clinical and preclinical dog studies, and the authors described the mechanism as compound specific[4], which is why a result for semaglutide cannot simply be carried over to tirzepatide.

The approved tablet also comes with strict instructions. It is taken on an empty stomach with up to 4 ounces of water and swallowed whole, and the patient waits at least 30 minutes before eating, drinking or taking other oral medicines[3]. A compounded oral product that does not state its absorption enhancer, or its own dosing conditions, gives the buyer no way to tell whether the same limits apply.

What the research on oral tirzepatide shows

No published human trial has tested tirzepatide taken by mouth or under the tongue. The nearest work is a 2026 formulation study that built an immediate-release tirzepatide tablet with sodium caprate as the absorption enhancer and measured blood levels in beagle dogs[5]. It is an early manufacturing study in animals, and it does not show what a person absorbs from a compounded tablet or drop.

A 2026 review of compounded GLP-1 products looked at what pharmacies were actually selling. Of the 33 products the authors identified that differed from the approved drugs, one-third contained tirzepatide, and the single-ingredient products were sublingual (82%) or orally disintegrating tablets (18%)[6]. The authors concluded that whether these formulations offer any advantage over the approved oral tablets had not been determined[6].

The approved tablet from the same maker

A reader who wants a once-daily pill from Lilly has an approved choice, but it is not tirzepatide. Foundayo is orforglipron, a small molecule rather than a peptide, with its own label, its own trials and its own self-pay price, all covered in orforglipron price. The approved semaglutide tablet is priced in Wegovy pill cost.

Questions to ask before paying for oral tirzepatide

Ask the seller which pharmacy compounds the product and under which section of the law, what absorption enhancer it contains, and how many milligrams the monthly price covers. Then ask what evidence the prescriber is relying on that the dose is absorbed at all, since the answer shapes whether a lower monthly price buys anything. For sellers whose fees have been read, the no-membership sellers board shows which ones add no membership on top of the medication.

FAQ

4 questions

Is there an FDA-approved oral tirzepatide?

No. Zepbound and Mounjaro, the two approved tirzepatide products, are both injections given under the skin once a week. Oral or sublingual tirzepatide is made by a compounding pharmacy.

How much does oral tirzepatide cost?

This page computes the typical monthly price of compounded oral tirzepatide from the sellers that publish one, and sets it beside the compounded sublingual and injection markets. Membership, consult and shipping fees are extra where a seller charges them.

Does oral tirzepatide work?

No published human trial has tested tirzepatide taken by mouth. The nearest study is a 2026 tablet-formulation study in beagle dogs. The approved oral semaglutide tablet needs an absorption enhancer, and its label estimates that only about 1% to 2% of the dose is absorbed.

Is there a weight-loss pill from the maker of Zepbound?

Yes, but it is not tirzepatide. Foundayo is orforglipron, a different molecule taken once daily, with its own label and self-pay price.

Sources

7 cited
  1. [1]Eli Lilly and Company (2026). ZEPBOUND (tirzepatide) injection, for subcutaneous use: Prescribing Information DailyMed, U.S. National Library of Medicine. Source
  2. [2]Eli Lilly and Company (2026). MOUNJARO (tirzepatide) injection, for subcutaneous use: Prescribing Information DailyMed, U.S. National Library of Medicine. Source
  3. [3]Novo Nordisk (2026). WEGOVY (semaglutide) injection and WEGOVY (semaglutide) tablets: Prescribing Information (revised 06/2026) Drugs@FDA, U.S. Food and Drug Administration. Source
  4. [4]Buckley ST, Bækdal TA, Vegge A, Maarbjerg SJ, Pyke C, Ahnfelt-Rønne J, Madsen KG, Schéele SG, Alanentalo T, Kirk RK, Pedersen BL, Skyggebjerg RB, Benie AJ, Strauss HM, Wahlund PO, Bjerregaard S, Farkas E, Fekete C, Søndergaard FL, Borregaard J, Hartoft-Nielsen ML, Knudsen LB (2018). Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist Science Translational Medicine. PMID 30429357
  5. [5]Im S, Lee JY, Kim JE (2026). Overcoming Gastric Barriers for Oral Peptide Delivery: QbD-Based Development of Sodium Caprate-Enabled Tirzepatide Tablets Pharmaceutics. PMID 42514904
  6. [6]Belcourt J, Sapowadia A, White CM (2026). Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown Annals of Pharmacotherapy. PMID 41689811
  7. [7]U.S. Food and Drug Administration (2026). FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss FDA. Source